Mineralys Therapeutics Q2 Earnings Call Highlights

Mineralys Therapeutics outlined its commercial launch strategy for lorundrostat, an aldosterone synthase inhibitor under FDA review for uncontrolled hypertension, ahead of the agency’s December 22 Prescription Drug User Fee Act target date. The company reported that clinical analyses demonstrated meaningful blood-pressure reductions in patients with chronic kidney disease and a 52% placebo-adjusted reduction in albuminuria, a marker of kidney injury. Exploratory proteomic findings from tw